3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
30
Carcinoma, Hepatocellular
13
Rectal Neoplasms
5
Sarcoma, Ewing
4
Osteosarcoma
4
Glioblastoma
4
Gastrointestinal Stromal Tumors
4
Colonic Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Esophageal Neoplasms
2
Chondrosarcoma
2
Bone Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Solid Malignant Tumors
1
Small Cell Lung Carcinoma
1
Recurrence
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Nivolumab
3
Oxaliplatin
2
Capecitabine
2
trifluridine tipiracil drug combination
1
sintilimab
1
relatlimab
1
regorafenib
1
dabrafenib
1
copanlisib
1
atezolizumab
1
Tiragolumab
1
Leucovorin
1
Immune Checkpoint Inhibitors
1
Fulvestrant
1
Fluorouracil
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinocerebellar Degenerations
×
regorafenib
×
1 year
×
Clear all
NCT05328908
2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3
Terminated
770 enrolled